Journal of Molecular Neuroscience

, Volume 21, Issue 1, pp 35–42 | Cite as

Screening for mutations in the RYR1 gene in families with malignant hyperthermia

  • Viviane P. Muniz
  • Helga C. A. Silva
  • Ana Maria C. Tsanaclis
  • Mariz Vainzof
Original Article


Malignant hyperthermia (MH) is a potentially lethal pharmacogenetic predisposition associated with a susceptibility to volatile anesthetics and depolarizing muscle relaxants that lead to a fulminant anesthetic crisis with hyperthermia, skeletal muscle rigidity, respiratory and metabolic acidosis, and muscle rhabdomyolysis. Malignant hyperthermia crises are caused by an abnormal regulation of the calcium release mechanism, which reflects the consequences of disturbed skeletal muscle calcium homeostasis. We screened 64 individuals of 27 unrelated families for the most frequently described mutations associated with MH in the genes RYR1 and CACNL1A3. We identified only one family with the Arg614Cys mutation but with a discordant segregating pattern to the in vitro contracture test (IVCT). To elucidate which other mechanism could lead to susceptibility in the members of this family, we tested it for further MH susceptibility loci. The same haplotype was shown to segregate with the individuals carrying the Arg614Cys mutation in chromosome 19; however, the other susceptible and equivocal individuals do not share this haplotype. Markers for the susceptible locus in chromosome regions 17q, 7q, 3q, and 5p did not segregate with the IVCT phenotype in the susceptible individuals, suggesting that the positivity of the IVCT could be attributable to other ambient factors.

Index Entries

Malignant hyperthermia RYR1 gene 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barone V., Massa O., Intravaia E., Bracco A., Di Martino A., Tegazzin V., et al. (1999) Mutation screening of the RYR1 gene and identification of two novel mutations in Italian malignant hyperthermia families. J. Med. Genet. 36, 115–118.PubMedGoogle Scholar
  2. Brandt A., Schleithoff L., Jurkat-Rott K., Klingler W., Baur C., and Lehmann-Horn F. (1999) Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test. Hum. Mol. Genet. 8, 2055–2062.PubMedCrossRefGoogle Scholar
  3. Brown R. L., Pollock A. N., Couchman K. G., Hodges M., Hutchinson D. O., Waaka R., et al. (2000) A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maoripedigree. Hum. Mol. Genet. 9, 1515–1524.PubMedCrossRefGoogle Scholar
  4. Chamley D., Pollock N. A., Stowell K. M., and Brown R. (2000) Malignant hyperthermia in infancy and identification of novel RYR1 mutation. Br. J. Anaesth. 84, 500–504.PubMedGoogle Scholar
  5. Deufel T., Sudbrack R., Feist Y., Rubsan B., Du Chesne I., Schafer K. L., et al. (1995) Discordance, in a malignant hyperthermia pedigree, between in vitro contracture test phenotypes and haplotypes for the MHS1 region on chromosome 19q12-13.2, comprising the C1840T transition in the RYR1 gene. Am. J. Hum. Genet. 56, 1334–1342.PubMedGoogle Scholar
  6. Fagerlund T. H., Islander G., Twetman E. R., and Berg K. (1995) A search for three known RYR1 gene mutations in 41 Swedish families with predisposition to malignant hyperthermia. Clin. Genet. 48, 12–16.PubMedCrossRefGoogle Scholar
  7. Gillard E., Otsu K., Fujii J., Khanna V. K., de Leon S., Derdemezi J., et al. (1991) A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 11, 751–755.PubMedCrossRefGoogle Scholar
  8. Gillard E., Otsu K., Fujii J., Duff K., de Leon S., Khanna V. K., et al. (1992) Polymorphisms and deduced amino acid substitutions in the coding sequence of the RYR1 gene in individuals with malignant hyperthermia. Genomics 13, 1247–1254.PubMedCrossRefGoogle Scholar
  9. Hogan K. (1997) To fire the train: a second malignanthyperthermia gene. Am. J. Hum. Genet. 60, 1303–1308.PubMedGoogle Scholar
  10. Jurkat-Rott K., McCarthy T., and Lehmann-Horn F. (2000) Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 23, 4–17.PubMedCrossRefGoogle Scholar
  11. Keating K., Giblin L., Lynch P., Quane K., Lehane M., Heffron J., and McCarthy T. (1997) Detection of a novel mutation in the ryanodine receptor gene in an Irish malignant hyperthermia pedigree: correlation of the IVCT response with the affected and unaffected haplotypes. J. Med. Genet. 34, 291–296.PubMedCrossRefGoogle Scholar
  12. Keating K., Quane K., Manning B., Lehane M., Hartung E., Censier K., et al. (1994) Detection of a novel RYR1 mutation in four malignant hyperthermia pedigrees. Hum. Mol. Genet. 10, 1855–1858.CrossRefGoogle Scholar
  13. Levitt R. C., Olckers A., Meyers S., Fletcher J. E., Rosemberg H., Isaacs H., and Meyers D. A. (1992) Evidence for the localization of a malignant hypethermia susceptibility locus (MSH2) to human chromosome 17q. Genomics 14, 562–566.PubMedCrossRefGoogle Scholar
  14. Lynch P. J., Krivosic-Horber R., Reyford H., Monnier N., Quane K., Adnet P., et al. (1997) Identification of homozygous and heterozygous individuals with a novel RYR1 mutation in a large kindred. Anesthesiology 86, 620–626.PubMedCrossRefGoogle Scholar
  15. Lynch P. J., Tong J., Lehane M., Mallet A., Giblin L., Heffron J. J., et al. (1999) A mutation in the transmembrane/luminal domain of the ryanodine receptor is associated with abnormal Ca2+ release channel function and severe central core disease. Proc. Natl. Acad. Sci. USA 96, 4164–4169.PubMedCrossRefGoogle Scholar
  16. MacLennan D. H. (1995) Discordance between phenotype and genotype in malignant hyperthermia. Curr. Opin. Neurol. 8, 397–401.PubMedCrossRefGoogle Scholar
  17. MacLennan D. H., Duff C., Zorzato F., Fujii J., Phillips M., Korneluk R. G., et al. (1990) Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 343, 559–561.PubMedCrossRefGoogle Scholar
  18. Manning B. M., Quane K. A., Ording H., and Urwyler A. (1998) Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hypethermia: genotype-phenotype correlation. Am. J. Hum. Genet. 62, 599–601.PubMedCrossRefGoogle Scholar
  19. McCarthy T. V., Healy J. M., Lehane M., and Heffron J. J. (1990) Recent developments in the molecular genetics of malignant hyperthermia: implications for future diagnosis at the DNA level. Acta Anaesthesiol. Belg. 41, 107–112.PubMedGoogle Scholar
  20. Moleshi R., Langlois S., Yam I., and Friedman J. M. (1998) Linkage of malignant hyperthermia and hyperkalemic periodic paralysis to the adult skeletal muscle sodium channel (SCN4A) gene in a large pedigree. Am. J. Med. Genet. 76, 21–27.CrossRefGoogle Scholar
  21. Monnier N., Romero N. B., Lerale J., Nvoche Y., Qi D., MacLennan D. H., Fardeau M., and Lunardi J. (2000) An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor. Hum. Mol. Genet. 9, 2599–2608.PubMedCrossRefGoogle Scholar
  22. Monnier N., Procaccio V., Stieglitz P., and Lunardi J. (1997) Malignant-hyperthermia susceptibility is associated with a mutation of the alpha-1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am. J. Hum. Genet. 60, 1316–1325.PubMedGoogle Scholar
  23. Monnier N., Krivosic-Horber R., Payen J. F., Kozak-Ribbens G., Nivoche Y., Adnet P., et al. (2002) Presence of two genetic traits in MH families: implication for genetic analysis, diagnosis and incidence of malignant hyperthermia susceptibility. Anesthesiology 97, 1067–1074.PubMedCrossRefGoogle Scholar
  24. Olckers A., Meyers D. A., Meyers S., Taylor E. W., Fletcher J. E., Rosenberg H., et al. (1992) Adult muscle sodium channel alpha-subunit is a gene cadidate for malignanthyperthermia susceptibility. Genomics 14, 829–831.PubMedCrossRefGoogle Scholar
  25. Ording H., Brancadoro V., Cozzolino S., Ellis F. R., Glauber V., Gonano E. F., et al. (1997) In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated lowrisk subjects. Acta Anesthesiol. Scand. 41, 955–966.Google Scholar
  26. Phillips M. S., Fujii J., Khanna V. K., DeLeon S., Yokobata K., de Jong P. J., and MacLennan D. H. (1996) The RYR1 gene. The structural organization of the human skeletal muscle ryanodine receptor (RYR1) gene. Genomics 15, 24–41.CrossRefGoogle Scholar
  27. Phillips M., Khanna V. K., de Leon S., Frodis W., Britt B., and MacLennan D. (1994) The substitution of Arg for Gly 2433 in the human sjkeletal muscle ryanodine receptor is associated with malignant hyperthermia. Hum. Mol. Genet. 3, 2181–2186.PubMedCrossRefGoogle Scholar
  28. Quane K. A., Healy J. M. S., Keating K. E., Manning B. M., Couch F. J., Palmucci L. M., et al. (1993) Mutations in theryanodine receptor gene in central core disease and malignant hyperthermia. Nat. Genet. 5, 51–55.PubMedCrossRefGoogle Scholar
  29. Quane K. A., Keating K., Healy J. M. S., Manning B. M., Krivosic-Horber R., Krivosic I., et al. (1994) Mutation screening of the RYR1 gene in malignant hyperthermia: detection of a novel Tyr to Ser mutation in a pedigree with associated central cores. Genomics 23, 236–239.PubMedCrossRefGoogle Scholar
  30. Robinson R. L., Curran J. L., Ellis F. R., Halsall P. J., Hall W. J., Hopkins P. M., et al. (2000) Multiple interacting gene products may influence susceptibility to malignant hyperthermia. Ann. Hum. Genet. 64, 307–320.PubMedCrossRefGoogle Scholar
  31. Robinson R. L., Monnier N., Wolz W., Jung M., and Reis A. (1997) A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees. Hum. Mol. Genet. 6, 953–961.PubMedCrossRefGoogle Scholar
  32. Rueffert H., Olthoff D., Deutrch C., and Froster U. G. (2001) Determination of a positive MH disposition without the in vitro contracture test in families carrying the RYR1 Arg614Cys mutation. Clin. Genet. 60, 117–124.PubMedCrossRefGoogle Scholar
  33. Sambuughin N., McWilliams S., Bantel A., Sivakumar K., and Nelson T. E. (2001a) Single-amino-acid deletion in the RYR1 gene, associated with malignant hyperthermia susceptibility and unusual contraction phenotype. Am. J. Hum. Genet. 69, 204–208.PubMedCrossRefGoogle Scholar
  34. Sambuughin N., Nelson T. E., Jankovic J., Xin C., Meissner G., Mullakandov M., et al. (2001b) Identification and funcional characterization of a novel mutation causing malignant hyperthermia in North American and South American families. Neuromuscul. Disord. 11, 530–537.PubMedCrossRefGoogle Scholar
  35. Sudbrak R., Golla A., Hogan K., Powers P., Gregg R., Du Chesne I., et al. (1993) Exclusion of malignant hyperthermia susceptibility (MHS) from a putative MHS2 locus on chromosome 17q and of the alpha-1, beta-1, and gamma subunits of the dihydropyridine receptor calcium channel as candidates for the molecular defect. Hum. Mol. Genet. 2, 857–862.PubMedCrossRefGoogle Scholar
  36. Sudbrak R., Procaccio V., Klausnitzer M., Curran J. L., Monsieurs K., Van Broeckhoven C., and Ellis R. (1995) Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1 Am. J. Hum. Genet. 56, 684–691.PubMedGoogle Scholar
  37. Terwilliger J. D. and Ott J. (1994) Handbook of Human Genetic Linkage, 1st ed., John Hopkins University Press, London, UK.Google Scholar
  38. Zhang Y., Chen H. S., Khanna V. K., De Leon S., Phillips M. S., Schappert K., et al. (1993) A mutation in the human ryanodine receptor gene associated with central core disease. Nat. Genet. 5, 46–50.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2003

Authors and Affiliations

  • Viviane P. Muniz
    • 1
  • Helga C. A. Silva
    • 2
  • Ana Maria C. Tsanaclis
    • 2
  • Mariz Vainzof
    • 1
  1. 1.Human Genome Research Center, Department of Biology, IBUniversity of Sao PauloSao PauloBrazil
  2. 2.Department of Pathology, FMUniversity of Sao PauloSao PauloBrazil

Personalised recommendations